DEA Stretches Virtual Controlled Drug Prescriptions to 2026
Published Date: 12/31/2025
Rule
Summary
The DEA and HHS are extending special telemedicine rules that let doctors prescribe controlled medications without an in-person visit through December 31, 2026. This helps patients who need these meds get care safely from home. Doctors and patients can keep using telehealth for these prescriptions without extra costs or delays during this time.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Keep Telemedicine Prescriptions Open
You can continue to get prescriptions for Schedule II-V controlled medications by telemedicine without an in-person medical visit if the rule's conditions are met. The temporary extension covers telemedicine prescribing from May 12, 2023 through December 31, 2026 and the rule is effective January 1, 2026 through December 31, 2026. The agencies note that in 2024 about 7 million prescriptions (roughly 16 percent of 44.6 million) were issued without a prior in-person medical evaluation.
Estimated Patient Cost Savings
DEA and HHS estimate patient cost savings from this extension: $18.4 million in the first year and a net present value of $17.2 million at a 7% discount rate. The agencies say the extension creates cost savings to patients and prescribers by avoiding the need for some in-person care during the extension period through December 31, 2026.
Fewer Requirements Than Final Rules
The temporary rule imposes fewer requirements than two related final rules that also address telemedicine prescribing. Practitioners who are covered by one or both of the Two Final Rules may still use this temporary extension (through December 31, 2026) so long as they meet the temporary rule's conditions, which can reduce compliance burdens during the extension.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans and others needing buprenorphine treatment can get care through telemedicine, making it easier and faster to access help. The government delayed these new rules to review feedback and make sure everything’s just right. This change means more people can get treatment from home without extra costs or trips to the doctor.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting March 21, 2025, veterans and others needing buprenorphine treatment can get care through telemedicine more easily. The government is delaying new rules to make sure everything’s just right and wants your thoughts on the delay. This change helps veterans keep their treatment going without extra trips, saving time and hassle.
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-17531, Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
The Drug Enforcement Administration (DEA) issues this temporary order to schedule 1-(1-(1-(4-bromophenyl)ethyl)piperidin-4- yl)-5,6-dichloro-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro brorphine or SR-14968); 5,6-dichloro-1-(1-(4- chlorobenzyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (commonly known as 5,6-dichloro desmethylchlorphine or SR-17018); 3-(3- (1-(1-(4-chlorophenyl)ethyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-1-yl)propanenitrile (commonly known as N-propionitrile chlorphine or cychlorphine); and 8-(1-(4-chlorophenyl)ethyl)-1-phenyl- 1,3,8-triazaspiro[4.5]decan-4-one (commonly known as spirochlorphine or R-6890), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, to schedule I under the Controlled Substances Act. DEA bases this action on a finding that placing 5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N- propionitrile chlorphine, and spirochlorphine in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess) or propose to handle these substances.
2026-17429, Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
The Drug Enforcement Administration (DEA) is issuing this temporary order to schedule three 7-hydroxymitragynine-related substances (mitragynine pseudoindoxyl, MGM-15, and MGM-16), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing mitragynine pseudoindoxyl, MGM-15, and MGM-16 in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle these three 7-hydroxymitragynine-related substances.
Previous / Next Documents
Previous: 2025-24113, Cotton Board Rules and Regulations: Adjusting Supplemental Assessment on Imports (2025 Amendments)
Starting March 1, 2026, importers of cotton and cotton products will see a change in how their supplemental fees are calculated. The USDA is lowering the value assigned to imported cotton to match the fees paid on U.S.-grown cotton, keeping things fair. This update also refreshes the Import Assessment Table to reflect recent changes since 2024.
Next: 2025-24127, Delegation of Authority to the Director of the Division of Investment Management
Starting December 31, 2025, the Director of the Division of Investment Management gets the power to approve or deny requests to keep certain investment info secret. This change helps the SEC work faster and saves resources by letting the Director handle these decisions directly. It mainly affects companies filing investment adviser info and speeds up how confidential info is managed.